Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
Primary Purpose
Autism, Autism Spectrum Disorder, Nonverbal Learning Disability
Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Memantine Hydrochloride
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Autism focused on measuring Autism, Massachusetts General Hospital
Eligibility Criteria
Inclusion Criteria:
- Male & female subjects ages 8-18 years (inclusive).
- Diagnostic Statistical Manual (DSM)-5 Autism Spectrum Disorder (ASD) diagnostic criteria as established by clinical diagnostic interview
- At least moderate severity of social impairment as measured by a total raw score of ≥85 on the parent/guardian-completed Social Responsiveness Scale-Second Edition (SRS-2)14 and a score of ≥4 on the clinician-administered Clinical Global Impression-Severity scale (CGI-S)17.
Exclusion Criteria:
- IQ ≤70 based on the Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary and Matrix Reasoning subtests
- Impaired communicative speech
- Subjects currently treated with the following medications (known to impact glutamate levels): Lamotrigine, Amantadine, N-acetylcysteine, D-cycloserine
- Subjects treated with a psychotropic medication not listed above on a dose that has not been stable for at least 4 weeks prior to study baseline.
- Co-administration of drugs that compete with memantine for renal elimination using the same renal cationic system, including hydrochlorothiazide, triamterene, metformin, cimetidine, ranitidine, quinidine, and nicotine
- Initiation of a new psychosocial intervention within 30 days prior to randomization.
- Subjects who are pregnant and/or nursing.
- Subjects with a history of non-febrile seizures without a clear and resolved etiology.
- Subjects with a history of or a current liver or kidney disease.
- Clinically unstable psychiatric conditions or judged to be at serious suicidal risk.
- Subjects who meet on the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-E) for alcohol or drug dependence or abuse. If the subject has a recent history of substance abuse, there will be a two-week washout period before initiating the trial as an added precaution. There are no known safety issues relating to memantine and recent history of substance abuse.
- Serious, stable or unstable systemic illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
- Subjects with severe hepatic impairment (LFTs > 3 times ULN).
- Subjects with genitourinary conditions that raise urine pH (e.g., renal tubular acidosis, severe infection of the urinary tract).
- Known hypersensitivity to memantine.
- Severe allergies or multiple adverse drug reactions.
- A history of intolerance or adequate exposure to memantine, as determined by the clinician.
- Investigator and his/her immediate family defined as the investigator's spouse, parent, child, grandparent, or grandchild.
Sites / Locations
- Massachusetts General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Memantine
Placebo
Arm Description
Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
Outcomes
Primary Outcome Measures
Clinical Global Impression-Improvement Scale (CGI-I)
The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale (1 to 7-- with higher numbers indicating more severely affected) that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.
Secondary Outcome Measures
Full Information
NCT ID
NCT03553875
First Posted
June 1, 2018
Last Updated
September 7, 2023
Sponsor
Massachusetts General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03553875
Brief Title
Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
Official Title
Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 13, 2018 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18.
This study consists of up to 6 visits to Massachusetts General Hospital.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism, Autism Spectrum Disorder, Nonverbal Learning Disability
Keywords
Autism, Massachusetts General Hospital
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Memantine
Arm Type
Active Comparator
Arm Description
Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Memantine Hydrochloride
Intervention Description
Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
Primary Outcome Measure Information:
Title
Clinical Global Impression-Improvement Scale (CGI-I)
Description
The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale (1 to 7-- with higher numbers indicating more severely affected) that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.
Time Frame
Baseline to 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male & female subjects ages 8-18 years (inclusive).
Diagnostic Statistical Manual (DSM)-5 Autism Spectrum Disorder (ASD) diagnostic criteria as established by clinical diagnostic interview
At least moderate severity of social impairment as measured by a total raw score of ≥85 on the parent/guardian-completed Social Responsiveness Scale-Second Edition (SRS-2)14 and a score of ≥4 on the clinician-administered Clinical Global Impression-Severity scale (CGI-S)17.
Exclusion Criteria:
IQ ≤70 based on the Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary and Matrix Reasoning subtests
Impaired communicative speech
Subjects currently treated with the following medications (known to impact glutamate levels): Lamotrigine, Amantadine, N-acetylcysteine, D-cycloserine
Subjects treated with a psychotropic medication not listed above on a dose that has not been stable for at least 4 weeks prior to study baseline.
Co-administration of drugs that compete with memantine for renal elimination using the same renal cationic system, including hydrochlorothiazide, triamterene, metformin, cimetidine, ranitidine, quinidine, and nicotine
Initiation of a new psychosocial intervention within 30 days prior to randomization.
Subjects who are pregnant and/or nursing.
Subjects with a history of non-febrile seizures without a clear and resolved etiology.
Subjects with a history of or a current liver or kidney disease.
Clinically unstable psychiatric conditions or judged to be at serious suicidal risk.
Subjects who meet on the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-E) for alcohol or drug dependence or abuse. If the subject has a recent history of substance abuse, there will be a two-week washout period before initiating the trial as an added precaution. There are no known safety issues relating to memantine and recent history of substance abuse.
Serious, stable or unstable systemic illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
Subjects with severe hepatic impairment (LFTs > 3 times ULN).
Subjects with genitourinary conditions that raise urine pH (e.g., renal tubular acidosis, severe infection of the urinary tract).
Known hypersensitivity to memantine.
Severe allergies or multiple adverse drug reactions.
A history of intolerance or adequate exposure to memantine, as determined by the clinician.
Investigator and his/her immediate family defined as the investigator's spouse, parent, child, grandparent, or grandchild.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chloe Hutt Vater, BA
Phone
617-724-7301
Email
chuttvater@mgh.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gagan Joshi, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chloe Hutt Vater, BA
Phone
617-724-7301
Email
chuttvater@mgh.harvard.edu
First Name & Middle Initial & Last Name & Degree
Gagan Joshi, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
36006807
Citation
Brignell A, Marraffa C, Williams K, May T. Memantine for autism spectrum disorder. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013845. doi: 10.1002/14651858.CD013845.pub2.
Results Reference
derived
Learn more about this trial
Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
We'll reach out to this number within 24 hrs